Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
7.68
-0.99 (-11.42%)
At close: Aug 15, 2025, 3:59 PM
-11.42% (1D)
| Bid | 7.82 |
| Market Cap | 235.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.11M |
| EPS (ttm) | -1.86 |
| PE Ratio (ttm) | -4.13 |
| Forward PE | -3.38 |
| Analyst | Buy |
| Ask | 7.86 |
| Volume | 1,158,224 |
| Avg. Volume (20D) | 1,595,106 |
| Open | 8.60 |
| Previous Close | 8.67 |
| Day's Range | 7.68 - 8.64 |
| 52-Week Range | 1.73 - 11.41 |
| Beta | 3.41 |
About SGMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+6.36%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
+12.4%
Sagimet Biosciences shares are trading higher after the company announced its Phase 3 Denifanstat acne therapy clinical trial met all primary and secondary endpoints.
2 months ago · seekingalpha.com
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FA...